Drugs / IBI3016
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07556796 | May 2026 → Oct 2027 expected | hypertensive disorder | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07352969 | Feb 2026 → Mar 2029 expected | hypertensive disorder | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting innoventbio.com ↗
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting innoventbio.com ↗ |
| 2024-08-02 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07556796 ↗ |
| Route | Subcutaneous | “IBI3016 or placebo, given subcutaneously” NCT07352969 ↗ |